According to the safety findings, four Grade Five serious adverse events were reported during the Phase II PALIZADE trial.

William Blair analyst Matt Phipps in a note to investors wrote that despite the patient deaths, the totality of the data ...

Lupus nephritis progression may be faster in patients with interstitial fibrosis/tubular atrophy (IFTA). Now a nomogram may predict it.

Positive topline results were announced from a phase 3 study of obinutuzumab in patients with lupus nephritis.

Kezar Life Sciences went all in on its autoimmune candidate zetomipzomib after a restructuring last year. | The voluntary ...

In the Phase III REGENCY study, Gazyva elicited superior complete renal response rates in patients with lupus nephritis ...

Roche has announced positive results from its phase III REGENCY study, showing that its drug Gazyva®/Gazyvaro® (obinutuzumab) ...

Kezar Life Sciences said it voluntarily suspended enrollment and dosing in a clinical trial of a treatment for an autoimmune kidney disease after four patients died.

Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus ...

After collecting a handful of oncology approvals since its first leukemia nod in 2013, Roche’s Biogen-partnered Rituxan ...

To provide more robust evidence for clinicians, investigators analyzed the efficacy and safety of biologics in patients with lupus nephritis using meta-regression analyses that adjusted for trials’ ...

Swiss pharma giant Roche has announced positive top-line results from the Phase III REGENCY study of Gazyva/Gazyvaro ...